Expert Review of Hematology最新文献

Bibliometric analysis of the research trends of thalassemia in the past decade. 近十年地中海贫血研究趋势的文献计量学分析。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-15 DOI: 10.1080/17474086.2026.2748721

Hong Liang, JianMing Luo

{"title":"Bibliometric analysis of the research trends of thalassemia in the past decade.","authors":"Hong Liang, JianMing Luo","doi":"10.1080/17474086.2026.2748721","DOIUrl":"10.1080/17474086.2026.2748721","url":null,"abstract":"Background: To date, many articles on thalassemia have been published, but the field still lacks systematic reviews. This bibliometric study maps global research trends and knowledge structures on thalassemia from 2015 to 2024, addressing the need for an integrated overview linking publication dynamics, thematic evolution and collaboration.Research design and methods: Articles on thalassemia were retrieved from the Web of Science Core Collection. The bibliometrix R package was used for statistical analysis and visualization of outputs, countries, institutions, authors, journals and keywords.Results: A total of 2,878 publications were identified, with annual output peaking in 2021 (333 papers). China ranks first in terms of the number of publications. Hemoglobin was the most prolific journal (n = 96), and Blood had the highest citation impact. Fucharoen S was the most productive author (n = 65), and Frangoul H was the most cited (n = 1,236). The United States, China and Italy formed the primary collaboration hubs. The top three high-frequency words are beta-thalassemia (492 times, 9%), disease (299 times, 7%), and children (246 times, 4%).Conclusions: Thalassemia research remains a strong academic focus. Current major topics include diagnostic innovation, genetic testing and pediatric care. Future efforts should prioritize translational studies, cross-regional collaboration and neglected areas such as adult quality of life and gene therapy accessibility.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reframing sickle cell disease care: improving care with an embedded primary care model for chronic comorbidity management. 重塑镰状细胞病护理：改善护理与嵌入式初级保健模式慢性合并症管理。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-05 DOI: 10.1080/17474086.2026.2744003

Robert M Cronin

{"title":"Reframing sickle cell disease care: improving care with an embedded primary care model for chronic comorbidity management.","authors":"Robert M Cronin","doi":"10.1080/17474086.2026.2744003","DOIUrl":"https://doi.org/10.1080/17474086.2026.2744003","url":null,"abstract":"Introduction: We are in a new era of unprecedented therapeutic possibilities in sickle cell disease (SCD). However, disease-modifying therapies alone will not fix a care system that leaves prevention, chronic comorbidity management, and mental health behind. Patient-centered SCD care must address the whole person, not hematology care alone.Areas covered: We review primary care and preventive needs within SCD, the current fragmented model, and a novel embedded primary care provider (PCP) model. PubMed and Google Scholar were searched from database inception through August 2026 for English-language literature on SCD, primary care, preventive care, mental health, care fragmentation, and embedded care models.Expert opinion: SCD is entering a new era of care; however, one glaring issue is the current fragmented care model. A model that puts patient goals at the center and makes primary care a core element can make today's evidence-based recommendations more achievable. The shift in SCD care is not about moving away from the hematologist, but building the comprehensive support that patients need. By embedding a PCP into SCD teams, programs may be able to deliver preventive care, address depression and anxiety, manage chronic disease, and translate guidelines into routine practice.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-7"},"PeriodicalIF":2.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoglobulins as replacement therapy in hematological malignancies: from historical hypogammaglobulinemia to the era of T-cell-engaging therapies. 免疫球蛋白作为血液恶性肿瘤的替代疗法：从历史上的低γ球蛋白血症到t细胞参与治疗的时代。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-05 DOI: 10.1080/17474086.2026.2744002

Andrea Duminuco, Laura Anastasia Caruso, Rossella Garro, Chiara Finocchiaro, Annalisa Santisi, Arianna Sbriglione, Alessandro Petronaci, Francesco Di Raimondo, Giuseppe Alberto Palumbo

{"title":"Immunoglobulins as replacement therapy in hematological malignancies: from historical hypogammaglobulinemia to the era of T-cell-engaging therapies.","authors":"Andrea Duminuco, Laura Anastasia Caruso, Rossella Garro, Chiara Finocchiaro, Annalisa Santisi, Arianna Sbriglione, Alessandro Petronaci, Francesco Di Raimondo, Giuseppe Alberto Palumbo","doi":"10.1080/17474086.2026.2744002","DOIUrl":"https://doi.org/10.1080/17474086.2026.2744002","url":null,"abstract":"Introduction: Secondary immunodeficiency (SID) with hypogammaglobulinemia is a frequent complication of B-cell hematological malignancies, arising from the disease and from an expanding range of B-cell-depleting and T-cell-engaging therapies. Immunoglobulin replacement therapy (IgRT) is widely used to prevent infection, yet the evidence underpinning this practice is surprisingly weak.Areas covered: The randomized trials, almost all conducted before 2000 and confined to chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), show a reduction in clinically documented infection (pooled relative risk [RR] 0.72) but no effect on mortality and an increased risk of adverse events. When high-risk-of-bias trials are excluded, even the infection benefit loses statistical significance (RR 0.80; 95% CI, 0.62-1.04). Contemporary real-world CLL data found no association between regular IgRT and fewer infection-related hospitalizations.Expert opinion: Against this backdrop, IgRT use continues to rise, driven partly by the profound hypogammaglobulinemia that follows CAR-T cells and bispecific antibodies, settings supported only by observational data. This narrative review synthesizes the mechanisms, setting-specific evidence, and practical management of IgRT, argues for a critical, stewardship-minded stance in which IgRT is reserved (severe hypogammaglobulinemia with recurrent or severe bacterial infection failing simpler measures), and outlines the adequately powered, modern-era trials needed to resolve the uncertainty.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-13"},"PeriodicalIF":2.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think? 真性红细胞增多症与代谢综合征：这两种疾病之间的关系比我们想象的要多吗？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-06-19 DOI: 10.1080/17474086.2026.2659700

Cem Selim, Nilgün Okşak, Uğur Fahri Yürekli

{"title":"Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?","authors":"Cem Selim, Nilgün Okşak, Uğur Fahri Yürekli","doi":"10.1080/17474086.2026.2659700","DOIUrl":"10.1080/17474086.2026.2659700","url":null,"abstract":"Background: Polycythemia vera (PV), the most common myeloproliferative neoplasm, is driven by JAK2 mutations and often coexists with metabolic syndrome (MS), a major cardiovascular risk factor. Few studies have examined oxidative stress as a potential link between PV and MS.Research design and methods: This observational case-control study included 36 PV patients (15 with MS) and 40 healthy volunteers between 2017 and 2023. Diagnosis followed 2016 WHO criteria. Patients with abnormal hematologic values, organ dysfunction, elevated CRP, or confounding comorbidities were excluded. Oxidative stress was assessed by spectrophotometric measurement of total antioxidant status (TAS) and total oxidant status (TOS).Results: TOS levels were significantly higher in PV-MS patients compared to PV alone (p < 0.05), and oxidative stress markers overall were elevated versus healthy controls (p < 0.05). No significant differences in TAS or TOS were observed between ELN high- and low-risk groups or among patients receiving hydroxyurea, aspirin, metformin, ACE inhibitors, and untreated patients (p > 0.05).Conclusions: Oxidative stress is markedly elevated in PV patients with MS, supporting a pathophysiological link between the two conditions. These findings highlight the importance of considering oxidative stress in the clinical evaluation of PV patients with metabolic syndrome.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1215-1222"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147671800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endogenous erythroid colony formation in the era of contemporary polycythemia vera diagnosis. 内源性红系集落形成时代对当代真性红细胞增多症的诊断。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-07-28 DOI: 10.1080/17474086.2026.2708709

Dijana Sefer, Danijela Lekovic

引用次数: 0

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes. 尼洛替尼治疗慢性髓性白血病：临床价值，现实世界的挑战，以及尼洛替尼片改善治疗结果的潜力

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-12 DOI: 10.1080/17474086.2026.2715450

Kendra Sweet, Srinivas Tantravahi, Paras Jain, Dan Douer

{"title":"Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.","authors":"Kendra Sweet, Srinivas Tantravahi, Paras Jain, Dan Douer","doi":"10.1080/17474086.2026.2715450","DOIUrl":"10.1080/17474086.2026.2715450","url":null,"abstract":"Introduction: Nilotinib has been shown to be highly effective for the treatment of chronic myeloid leukemia (CML) and advancing patients to treatment-free remission (TFR). However, its efficacy and safety may be compromised by nonadherence due to its twice-daily fasting requirement. A reduced-dose nilotinib tablet may address these limitations.Areas covered: PubMed search (1966 to July 2026) for papers related to the pathology, etiology, and treatment of CML, pivotal clinical trials and real-world studies for tyrosine kinase inhibitors (TKI) focusing on nilotinib, and recent pharmacokinetic and adherence research, including data on the nilotinib tablet. Nilotinib achieves more rapid deep molecular responses and TFR rates vs imatinib. Nilotinib also offers efficacy comparable to dasatinib, bosutinib, and asciminib. Twice-daily administration with fasting requirements for nilotinib contribute to real-world nonadherence, which often remains undetected by healthcare professionals, undermines TFR goals, and may increase the risk of cardiovascular adverse events.Expert opinion: The nilotinib tablet provides bioequivalent exposure to nilotinib capsules under overnight fasted conditions at a reduced dose without a food effect on absorption. It offers a solution to the complex dosing regimen for nilotinib capsules, potentially supporting better adherence and outcomes with reduced concern about food-related inconvenience.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1179-1194"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148723882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome. 预防性tocilizumab用于多发性骨髓瘤双特异性t细胞参与者：减轻细胞因子释放综合征的现有证据和临床考虑

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-10 DOI: 10.1080/17474086.2026.2716326

Hana Kurz, Jessica McElwee, Grace Elsey, James A Davis, Shebli Atrash, Donald C Moore

引用次数: 0

Supporting leukemia patients when the real-world gets in the way: improving adherence to oral treatment. 在现实生活中支持白血病患者：提高口服治疗的依从性。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-11 DOI: 10.1080/17474086.2026.2716328

Lindsey Davis, Solomon Ayehu, Benyam Muluneh

引用次数: 0

Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma? Daratumumab和透明质酸酶-fihj，高风险阴燃性多发性骨髓瘤的单一疗法：预防活动性骨髓瘤的转变？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-10 DOI: 10.1080/17474086.2026.2715442

Bartosz Puła, Wiktoria Ryżewska, Artur Handziuk, Agata Tyczyńska, Tadeusz Kubicki

{"title":"Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?","authors":"Bartosz Puła, Wiktoria Ryżewska, Artur Handziuk, Agata Tyczyńska, Tadeusz Kubicki","doi":"10.1080/17474086.2026.2715442","DOIUrl":"10.1080/17474086.2026.2715442","url":null,"abstract":"Introduction: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder with heterogeneous risk of progression to active multiple myeloma. Most patients are managed with observation, but selected high-risk patients may benefit from early intervention. Daratumumab, an anti-CD38 monoclonal antibody, has recently emerged as a promising therapeutic option in this setting.Areas covered: This review summarizes the biological rationale for targeting CD38 in SMM, including the immune-mediated and direct antimyeloma effects of daratumumab. It discusses current approaches to SMM risk stratification, with an emphasis on the Mayo 20/2/20 and IMWG 2020 models. The review also covers clinical evidence supporting daratumumab, particularly the phase III AQUILA trial, which showed that fixed-duration subcutaneous daratumumab delayed progression to active multiple myeloma compared with active monitoring. Ongoing studies of daratumumab-based combinations and other anti-CD38 strategies are also discussed.Expert opinion: Daratumumab marks an important step toward early, disease-modifying therapy for high-risk SMM. Future strategies may include triplets, quadruplets, and immune-based combinations to achieve deeper responses and a possible functional cure. However, these approaches must be balanced against the risks of toxicity, infection, immunosuppression, and overtreatment. Precise patient selection remains the key challenge.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1135-1146"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between the lactate dehydrogenase-to-albumin ratio and prognosis in ICU sepsis-induced coagulopathy patients. ICU脓毒症致凝血病患者乳酸脱氢酶与白蛋白比值与预后的关系

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-10 DOI: 10.1080/17474086.2026.2715457

Yufeng Jin, Dong He, Yulong Xue

{"title":"Association between the lactate dehydrogenase-to-albumin ratio and prognosis in ICU sepsis-induced coagulopathy patients.","authors":"Yufeng Jin, Dong He, Yulong Xue","doi":"10.1080/17474086.2026.2715457","DOIUrl":"10.1080/17474086.2026.2715457","url":null,"abstract":"Background: Sepsis-induced coagulopathy (SIC) is a severe complication of sepsis with high mortality. The lactate dehydrogenase-to-albumin ratio (LAR), a composite marker of cell injury and inflammation, is associated with sepsis prognosis, but its role in SIC remains unclear.Research design and methods: Data from 1,500 SIC patients in the Medical Information Mart for Intensive Care database were used. The primary outcome was 30-day all-cause mortality and the secondary outcome was 90-day mortality. Kaplan-Meier curves, Cox regression, restricted cubic splines, and subgroup analyses were used.Results: Compared with the low-LAR group, medium- and high-LAR groups had higher 30- and 90-day mortality rates (p < 0.001). The fully adjusted Cox model showed positive correlations of ln(LAR) with 30-day (HR = 1.17, 95% CI: 1.03-1.31, p = 0.013) and 90-day mortality rates (HR = 1.17, 95% CI: 1.04-1.30, p = 0.007). The relationship between ln(LAR) and 30-day mortality rate was nonlinear (P-non-linear = 0.007), with an inflection point at 4.57. An interaction was observed for dobutamine therapy (P-interaction = 0.03).Conclusions: LAR is associated with poor prognosis in patients with SIC, especially once ln(LAR) surpasses 4.57.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1205-1214"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0